search
Back to results

Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function

Primary Purpose

Borderline Hypertension

Status
Completed
Phase
Phase 2
Locations
Finland
Study Type
Interventional
Intervention
Epicatechin
Microcrystalline cellulose
Sponsored by
Danisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Borderline Hypertension focused on measuring FMD, epicatechin, apple polyphenol, borderline hypertension

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Borderline hypertension
  • Otherwise healthy
  • Aged 40-65 years (inclusive)
  • Not consuming high amounts (over 20 mg daily) of flavonoids

Exclusion Criteria:

  • BMI >32 kg/m2
  • Total serum cholesterol ≥ 8 mmol/l
  • Any abnormal safety laboratory parameter or abnormal finding in ECG evaluated to be clinically significant
  • Coronary artery disease
  • Pregnancy or lactating
  • Alcohol abuse as evaluated by medical history
  • Regular smoking/using nicotine products
  • Diabetes mellitus
  • Apple allergy
  • Use of lipid lowering medications
  • Regular use of any medication that is known or believed to affect endothelial function or blood vessel constriction
  • Any other condition or medication that in the opinion of the investigator would interfere with the evaluation of the study results or constitute a health risk for the subject
  • High consumption of vitamin products, herbal remedies or products containing flavonoids

Sites / Locations

  • University of Turku

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Epicatechin

Microcrystalline cellulose

Arm Description

The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.

The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.

Outcomes

Primary Outcome Measures

Brachial flow-mediated dilation test (FMD)
ultrasonography, FMDmax%

Secondary Outcome Measures

Nitrate-mediated vasodilatation response (NMD)
ultrasonography, NMDmax%
Circulating biomarkers of vascular function
depends on the biomarker
BP
Plasma epicatechin concentration
HPLC

Full Information

First Posted
September 14, 2012
Last Updated
April 7, 2014
Sponsor
Danisco
Collaborators
University of Turku, 4Pharma Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01690676
Brief Title
Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function
Official Title
The Effect of an Apple Polyphenol Extract Rich in Epicatechin and Flavan-3-ol Oligomers (Evesse™ EPC) on Brachial Artery Flow-mediated Vasodilatory Function (FMD)in Volunteer Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Danisco
Collaborators
University of Turku, 4Pharma Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Effect of apple polyphenols on FMD.
Detailed Description
The aim of this single centre, repeated-dose, double-blind, placebo-controlled, crossover study is to test the hypothesis that an orally ingested apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers improves brachial artery endothelium-dependent vasodilation function (FMD) in volunteer subjects with borderline hypertension. FMD and endothelium-independent nitrate-mediated vasodilatation (NMD) of the left brachial artery will be investigated with ultrasonography at the start and end of both treatment periods. Biomarkers of vascular function and epicatechin (and metabolite) concentrations will be determined from blood samples taken at the start and end of both treatment periods. Diet diary data will be collected for the evaluation of the possible effects of diet on the study results. Adverse events data will be collected throughout the study. Safety laboratory determinations will be performed at the last visit of both treatment periods.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Borderline Hypertension
Keywords
FMD, epicatechin, apple polyphenol, borderline hypertension

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
57 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Epicatechin
Arm Type
Active Comparator
Arm Description
The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
Arm Title
Microcrystalline cellulose
Arm Type
Placebo Comparator
Arm Description
The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
Intervention Type
Dietary Supplement
Intervention Name(s)
Epicatechin
Intervention Type
Dietary Supplement
Intervention Name(s)
Microcrystalline cellulose
Primary Outcome Measure Information:
Title
Brachial flow-mediated dilation test (FMD)
Description
ultrasonography, FMDmax%
Time Frame
At first visits of both periods baseline FMD will be recorded followed by FMD recording 1.5 hours after first dose. After 4 weeks intervention, at last visits of both periods FMD will be recorded, last dose will be taken and FMD recorded 1.5 hours after.
Secondary Outcome Measure Information:
Title
Nitrate-mediated vasodilatation response (NMD)
Description
ultrasonography, NMDmax%
Time Frame
At the first and last visits of both periods, approximately 10 minutes after FMD.
Title
Circulating biomarkers of vascular function
Description
depends on the biomarker
Time Frame
Once at the first visit of both periods and once at the last visit of both periods. Blood sampling prior to the morning dose and appr. 2 h thereafter
Title
BP
Time Frame
Once at the first visit of both periods and once at the last visit of both periods. Blood pressure will be recorded twice prior to the morning dose.
Title
Plasma epicatechin concentration
Description
HPLC
Time Frame
At the first visit of both periods and at the last visit of both periods. Blood sampling prior to the morning dose and appr. 2 h thereafter

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Borderline hypertension Otherwise healthy Aged 40-65 years (inclusive) Not consuming high amounts (over 20 mg daily) of flavonoids Exclusion Criteria: BMI >32 kg/m2 Total serum cholesterol ≥ 8 mmol/l Any abnormal safety laboratory parameter or abnormal finding in ECG evaluated to be clinically significant Coronary artery disease Pregnancy or lactating Alcohol abuse as evaluated by medical history Regular smoking/using nicotine products Diabetes mellitus Apple allergy Use of lipid lowering medications Regular use of any medication that is known or believed to affect endothelial function or blood vessel constriction Any other condition or medication that in the opinion of the investigator would interfere with the evaluation of the study results or constitute a health risk for the subject High consumption of vitamin products, herbal remedies or products containing flavonoids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kirsti Tiihonen, PhD
Organizational Affiliation
Danisco
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Olli Raitakari, MD
Organizational Affiliation
University of Turku, Turku, Finland, The Research Centre of Applied and Preventive Cardiovascular Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pia Salo, MD, PhD
Organizational Affiliation
University of Turku, Turku, Finland, The Research Centre of Applied and Preventive Cardiovascular Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Lithonius
Organizational Affiliation
Clinical Research Services Turku
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mika Scheinin, MD, PhD
Organizational Affiliation
Clinical Research Services Turku
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jari Turunen, MSc
Organizational Affiliation
4Pharma Ltd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Turku
City
Turku
Country
Finland

12. IPD Sharing Statement

Citations:
PubMed Identifier
29078780
Citation
Saarenhovi M, Salo P, Scheinin M, Lehto J, Lovro Z, Tiihonen K, Lehtinen MJ, Junnila J, Hasselwander O, Tarpila A, Raitakari OT. The effect of an apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers on brachial artery flow-mediated vasodilatory function in volunteers with elevated blood pressure. Nutr J. 2017 Oct 27;16(1):73. doi: 10.1186/s12937-017-0291-0.
Results Reference
derived

Learn more about this trial

Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function

We'll reach out to this number within 24 hrs